Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151418 | 0.92 | CXCR4 (0.57) | CXCR4SMN1; SMN2KEAP1SIGMAR1HRH3 | |
| SCHEMBL6674597 | 0.88 | SMN1; SMN2 (0.56) | CXCR4SMN1; SMN2KEAP1SIGMAR1HRH3 | |
| SCHEMBL5569626 | 0.88 | CXCR4 (0.91) | CXCR4SMN1; SMN2SIGMAR1HRH3HRH2 | |
| Hydrochloric Acid SCHEMBL5570628 | 0.86 | CXCR4 (0.87) | CXCR4SMN1; SMN2SIGMAR1HRH3HRH2 | |
| SCHEMBL9241446 | 0.86 | CXCR4 (0.95) | CXCR4SMN1; SMN2SIGMAR1HRH3HRH2 | |
| SCHEMBL151845 | 0.86 | CXCR4 (0.87) | CXCR4SMN1; SMN2SIGMAR1HRH3HRH2 | |
| SCHEMBL416345 | 0.85 | SMN1; SMN2 (0.50) | CXCR4SMN1; SMN2KEAP1SIGMAR1HRH3 | |
| SCHEMBL599000 | 0.84 | CXCR4 (1.00) | CXCR4SMN1; SMN2SIGMAR1HRH3HRH2 | |
| Hydrochloric Acid SCHEMBL27141329 | 0.83 | GLA (0.48) | CXCR4SMN1; SMN2KEAP1SIGMAR1HRH3 | |
| SCHEMBL23337601 | 0.83 | CXCR4 (0.74) | CXCR4SMN1; SMN2SIGMAR1HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| EP-2118110-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
| EP-2118110-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-2074083-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-01 | — | — | EP | disclosed |
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008112851-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008050168-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | CXCR4 421/4885SMN1; SMN2 3719/4885KEAP1 906/4885 |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, OAT | CXCR4 367/4885SMN1; SMN2 3457/4885KEAP1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.